ELREXFIO® (elranatamab-bcmm) and Bispecific Antibodies for Multiple Myeloma
How Bispecific Antibodies like Elrexfio Work, What to Expect, and Why Safety Monitoring Matters
Bispecific antibodies are an important type of immunotherapy used in multiple myeloma care, especially for patients who have relapsed after prior treatment. In this video, health professionals explains how bispecific therapies work by helping the immune system recognize and attack myeloma cells.
You’ll also hear a real patient story that highlights what living with multiple myeloma can look like over time—how relapse is identified through lab monitoring, how response is tracked, and how treatment planning can support quality of life.
Topics covered in this video
- Why bispecific antibodies are changing myeloma treatment options
- What ELREXFIO® (elranatamab-bcmm) is and how it works
- Monitoring response through labs (including light chains)
- Treatment scheduling and clinic monitoring
- Understanding potential side effects, including CRS
- What deep response can mean (including MRD negativity)
- Living well with multiple myeloma and planning for the future
Learn more about available support and resources with the Pfizer Patient Access Navigator.
IMPORTANT SAFETY INFORMATION (ISI) + BOXED WARNING
Please see Full Prescribing Information, including Boxed Warning: https://www.elrexfio.com/
Adverse Event Reporting:
Side effects may be reported to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
This educational content was supported by Pfizer. The International Myeloma Foundation provides independent patient education and does not provide individual medical advice.
